AU Patent

AU2016200133B2 — Oral formulations and lipophilic salts of methylnaltrexone

Assigned to Wyeth LLC · Expires 2017-09-07 · 9y expired

What this patent protects

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. WO 2011/112816 PCT/US2O1 1/1)27913 co a) co CD5 0- O C) LOO C C14c 0) CD L) C) CN~C C CDI \ " * - C eseei~ %CD C~ 00)…

USPTO Abstract

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. WO 2011/112816 PCT/US2O1 1/1)27913 co a) co CD5 0- O C) LOO C C14c 0) CD L) C) CN~C C CDI \ " * - C eseei~ %CD C~ 00)C CN CcjDcODE E\ ese4a %

Drugs covered by this patent

Patent Metadata

Patent number
AU2016200133B2
Jurisdiction
AU
Classification
—
Expires
2017-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.